PRALUENT is a PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) inhibitor antibody indicated as adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-cholesterol (LDL-C).
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of PRALUENT (alirocumab) injection brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the PRALUENT (alirocumab) injection medicine cost price in India.
The order for PRALUENT (alirocumab) injection will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Alirocumab (trade name Praluent) is a biopharmaceutical drug approved by the FDA on July 24, 2015 as a second line treatment for high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment. It is a human monoclonal antibody that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors, and it was the first such agent to receive FDA approval.
PRALUENTTM (alirocumab) injection, for subcutaneous use Initial U.S. Approval: 2015
Generic Name: Alirocumab
Injection: 75 mg/mL or 150 mg/mL solution in a single-dose pre-filled pen
• Injection: 75 mg/mL or 150 mg/mL solution in a single-dose pre-filled syringe
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand PRALUENT (alirocumab) injection on prescription and Import License in Patient's Name only.
For overseas patients, PRALUENT (alirocumab) injection can be made available in Send your enquiry to find PRALUENT (alirocumab) injection in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For PRALUENT (alirocumab) injection Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
FDA Approves Praluent® (alirocumab) to Prevent Heart Attack, Stroke and Unstable Angina Requiring Hospitalization For More Details
FDA Expands Indication for PCSK9 Alirocumab (Praluent) For More Details